Surrozen, Inc./DE
SRZN · XNASCIK 1824893fmd_1FVHXKBTTA6GTZSN3A7BSF8MM4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 13 | 0 | 11 | 3 |
| Research and development | 26 | 40 | 37 | 27 | 21 | 29 |
| Total operating expenses | 33 | 54 | 57 | 46 | 36 | 46 |
| Operating income | (33) | (54) | (44) | (46) | (26) | (42) |
| Interest and investment income | 0 | 0 | 1 | 2 | 2 | 3 |
| Other non-operating income (expense) | 0 | (0) | 8 | 0 | (19) | (26) |
| Income before taxes | – | – | – | – | (64) | (242) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (64) | (242) |
| Net income | (33) | (55) | (36) | (43) | (64) | (242) |